期刊
CARDIOLOGY CLINICS
卷 34, 期 3, 页码 413-+出版社
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.ccl.2016.04.003
关键词
Pulmonary hypertension; Chronic obstructive pulmonary disease; Interstitial lung disease; Obstructive sleep apnea; Endothelin receptor antagonist; Phosphodiesterase inhibitor; Prostacyclin; Soluble guanylate cyclase stimulator
资金
- National Heart, Lung, and Blood Institute [RO1 HL 123965]
- Bayer
- Gilead
- Lung Biotechnology
- United Therapeutics
Pulmonary hypertension (PH) associated with chronic lung disease (WHO group 3) is the second leading cause of PH and is associated with increased morbidity and mortality. Elevation of pulmonary arterial pressure (PAP) is usually moderate and correlates with severity of lung disease. In a small minority, PAP may approach that seen in WHO group 1 pulmonary arterial hypertension (PAH). Current medications for treating PAH have not shown benefit in controlled trials of group 3 PH and their routine use is discouraged. Patients with severe group 3 PH should be considered for referral to expert centers or entry into clinical trials.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据